SCHEMBL10242953

SCHEMBL10242953

CCCCNC(=O)c1cccc(-c2cnc3ccccc3c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.62
MKNK2 Q9HBH9 2/20 0.62
MAP4K5 Q9Y4K4 2/20 0.62
CSNK1G2 P78368 1/20 0.62
CLK4 Q9HAZ1 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.58
CDK8 P49336 3/20 0.55
MMP9 P14780 1/20 0.52
SERPINE1 P05121 1/20 0.51
RXFP1 Q9HBX9 1/20 0.50
KDM4B O94953 1/20 0.49
JAK2 O60674 1/20 0.49
CHEK2 O96017 1/20 0.49
PRKCG P05129 1/20 0.49
CDK1 P06493 1/20 0.49
FES P07332 1/20 0.49
RET P07949 1/20 0.49
ROS1 P08922 1/20 0.49
FER P16591 1/20 0.49
FLT1 P17948 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242977 0.84 HDAC3 (0.61) SMN1; SMN2DRD2DRD3TRPV1NAAA
SCHEMBL1925893 0.81 SMN1; SMN2 (0.77) SMN1; SMN2DRD2DRD3NAAAHDAC1
SCHEMBL5020897 0.81 HDAC3 (0.61) SMN1; SMN2DRD2DRD3TRPV1NAAA
SCHEMBL31055462 0.79 SMN1; SMN2 (0.60) MAP4K4SMN1; SMN2CDK8KDRCAMK2D
SCHEMBL10242958 0.78 SMN1; SMN2 (0.67) SMN1; SMN2RXFP1KDM4BCAMK2DNAAA
SCHEMBL1679117 0.78 PRKD3 (0.71) MAP4K4MKNK2MAP4K5CSNK1G2CLK4
SCHEMBL31055400 0.78 SMN1; SMN2 (0.55) SMN1; SMN2DRD2DRD3NAAAHDAC1
SCHEMBL18943848 0.78 MAP4K4 (1.00) MAP4K4MKNK2MAP4K5CSNK1G2CLK4
SCHEMBL10242934 0.77 SMN1; SMN2 (0.65) SMN1; SMN2HDAC1HDAC2HDAC3KMT2A
SCHEMBL2971278 0.77 MAP4K4 (0.50) MAP4K4MKNK2MAP4K5CSNK1G2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MAP4K4 4273/4885MKNK2 4059/4885MAP4K5 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.